• SPX
  • $5,969.34
  • 0.35 %
  • $20.63
  • DJI
  • $44,296.51
  • 0.97 %
  • $426.16
  • N225
  • $38,283.85
  • 0.68 %
  • $257.68
  • FTSE
  • $8,262.08
  • 1.38 %
  • $112.81
  • IXIC
  • $19,003.65
  • 0.16 %
  • $31.23
Bright Minds Biosciences Inc. (DRUG) Stock Price, News & Analysis

Bright Minds Biosciences Inc. (DRUG) Stock Price, News & Analysis

Currency in USD Disclaimer

$35.22

$2.84

(8.77%)

Day's range
$31.41
Day's range
$36.72
50-day range
$0.94
Day's range
$79.02
  • Country: CA
  • ISIN: CA10919W4056
52 wk range
$0.93
Day's range
$79.02


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 747.51
  • Piotroski Score 2.00
  • Grade N/A
  • Symbol (DRUG)
  • Company Bright Minds Biosciences Inc.
  • Price $35.22
  • Changes Percentage (8.77%)
  • Change $2.84
  • Day Low $31.41
  • Day High $36.72
  • Year High $79.02

Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 11/27/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $0.00
  • High Stock Price Target $0.00
  • Low Stock Price Target $0.00
  • Potential Upside/Downside N/A
  • Consensus Rating Neutral
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$0.98
  • Trailing P/E Ratio -1.14
  • Forward P/E Ratio -1.14
  • P/E Growth -1.14
  • Net Income $-7,372,225

Income Statement

Quarterly

Annual

Latest News of DRUG

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Bright Minds Biosciences Inc. Frequently Asked Questions

  • What is the Bright Minds Biosciences Inc. stock price today?

    Today's price of Bright Minds Biosciences Inc. is $35.22 — it has increased by +8.77% in the past 24 hours. Watch Bright Minds Biosciences Inc. stock price performance more closely on the chart.

  • Does Bright Minds Biosciences Inc. release reports?

    Yes, you can track Bright Minds Biosciences Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Bright Minds Biosciences Inc. stock forecast?

    Watch the Bright Minds Biosciences Inc. chart and read a more detailed Bright Minds Biosciences Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is Bright Minds Biosciences Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Bright Minds Biosciences Inc. stock ticker.

  • How to buy Bright Minds Biosciences Inc. stocks?

    Like other stocks, DRUG shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Bright Minds Biosciences Inc.'s EBITDA?

    Bright Minds Biosciences Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Bright Minds Biosciences Inc.’s financial statements.

  • What is the Bright Minds Biosciences Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is 0, which equates to approximately 0.00%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Bright Minds Biosciences Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Bright Minds Biosciences Inc.'s financials relevant news, and technical analysis. Bright Minds Biosciences Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Bright Minds Biosciences Inc. stock currently indicates a “sell” signal. For more insights, review Bright Minds Biosciences Inc.’s technical analysis.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.